Mylan Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrine Injection, USP) Auto-Injector
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Elijah Cummings Says Mylan's (MYL) Meager Discount Merely 'PR Move'
August 25, 2016 10:42 AM EDTElijah Cummings Says Mylan's (Nasdaq: MYL) Meager Discount Merely 'PR Move'
... MoreMylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
August 25, 2016 10:33 AM EDTWells Fargo analyst David Maris weighed in on Mylan (NASDAQ: MYL) after the company announced it will expand its existing EpiPen access program with a $300 savings card and increased eligibility, amid mounting political pressure.
Maris said while a good start, these steps do not go far enough to address the underlying issues the Senate and many parents are concerned about, and as such, they believe an FTC investigation and Senate hearings are still a possibility.
The analyst said the steps... More
Mylan (MYL) Gains Early After Taking Action on EpiPen Pricing
August 25, 2016 7:51 AM EDTAfter dropping sharply over the past few sessions on headline risk related to EpiPen pricing, Mylan (NASDAQ: MYL) shares are gaining 3% early after the company announced plans to reduce patient cost through savings card which will cover up to $300 for their EpiPen 2-Pak.
... More
